CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 49 enrolled
Drug / intervention
Januvia +1 moredrug
Likely dose
Januvia 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00411411
NCT00411411Phase 3Completed
CompareCT.gov

Phase 3, Double Blinded, Placebo Controlled Study of the Effects of 12 Weeks DPP-IV Inhibitor Treatment on Secretion and Action of the Incretin Hormones in Patients With Type 2 Diabetes

University Hospital, Gentofte, Copenhagen·interventional·Posted Dec 14, 2006·Updated Aug 13, 2014

In Brief

A Phase 3 clinical trial evaluating Januvia and Placebo for Type 2 Diabetes. Completed, enrolled 49 participants across 1 site.

Detailed Summary

We wish to evaluate the effect of long term treatment with a DPP-IV inhibitor on the function of the incretin hormones Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by DPP-IV inhibitor (Januvia®) treatment significantly ameliorates the impaired secretion and potency of GLP-1 and leads to a restoration of the lost action of GIP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesDenmark
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2006
Enrollment StartFeb 1, 2007
Primary CompletionFeb 1, 2009
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.6 years ago

Interventions

Januviadrug

200 mg t.i.d

Placebodrug

Placebo